Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Back
Share this video  

iwAL 2018 | Target antigens for T-cell engager therapies in ALL and AML

Marion Subklewe • 17 Feb 2018
iwAL 2018
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia Antibodies

T-cell engaging antibodies are more straightforward to deisgn and use in acute lymphoblastic leukemia (ALL) compared with acute myeloid leukemia (AML), and have thus had more success. Here, Marion Subklewe, MD, of LMU-University Hospital Munich, Munich, Germany, explains the reasons for this difference and how we can improve response rates to this type of therapy in AML. This video was recorded at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL.

More from Marion Subklewe

1:43
CD33-TIM3 dual CAR T-cells enhance specificity of AML treatment
Marion Subklewe • 9 Dec 2023
1:04
MP0533, a CD3-engaging DARPin, in R/R AML or MDS/AML: preliminary results of a Phase I/IIa trial
Marion Subklewe • 9 Dec 2023
1:42
Dose escalation of RO7283420, a HLA-A2-WT1 CD3 T-cell bispecific antibody, in R/R AML
Marion Subklewe • 9 Dec 2023
2:33
Novel immunotherapies in AML and insights into the future of the treatment landscape
Marion Subklewe • 9 Dec 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals